Antihypertensive Drugs Market by Drug Class, Form, Indication, Distribution Channel, End-User

List of Tables

The Antihypertensive Drugs Market is projected to reach USD 33.99 billion by 2030 from USD 23.65 billion in 2022, at a CAGR of 4.63% during the forecast period.

Global Antihypertensive Drugs Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 23.65 billion
Estimated Year Value [2023]	USD 24.70 billion
Forecast Year Value [2030]	USD 33.99 billion
CAGR (%)	4.63%

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Antihypertensive Drugs Market.

Based on Drug Class, market is studied across Alpha-Blockers, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Beta-Blockers, Calcium Channel Blockers, Diuretics, Renin Inhibitors, and Vasodilators. The Diuretics is projected to witness significant market share during forecast period.

Based on Form, market is studied across Intravenous Injections, Oral Tablets/Capsules, and Transdermal Patches. The Transdermal Patches is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Primary Hypertension and Secondary Hypertension. The Primary Hypertension is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Offline and Online. The Offline is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Home Care Facilities and Hospitals & Clinics. The Hospitals & Clinics is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Antihypertensive Drugs Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Antihypertensive Drugs Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Antihypertensive Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alembic Pharmaceuticals Limited, Alkem Laboratories, Apikos Pharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Centurion Remedies Private Limited, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Lupin Ltd., Merck & Co., Inc., Novartis AG, Sanofi S.A., Saphnix Lifesciences, Schwitz Biotech, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Zydus Lifesciences Limited.

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Antihypertensive Drugs Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Antihypertensive Drugs Market?

3. What is the competitive strategic window for identifying opportunities in the Antihypertensive Drugs Market?

4. What are the latest technology trends and regulatory frameworks in the Antihypertensive Drugs Market?

5. What is the market share of the leading vendors in the Antihypertensive Drugs Market?

6. Which modes and strategic moves are suitable for entering the Antihypertensive Drugs Market?

Product Code: MRR-B1685377829A

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Antihypertensive Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Surging prevalence of hypertension, along with the growing geriatric population
  - 5.1.1.2. Increase in healthcare expenditure worldwide
  - 5.1.1.3. Growing consumer awareness of early diagnosis and treatment
- 5.1.2. Restraints
  - 5.1.2.1. Stringent approval process and huge costs involved in drug development
- 5.1.3. Opportunities
  - 5.1.3.1. Introduction of a new class of antihypertensive drugs
  - 5.1.3.2. Surge in approvals of novel drugs from regulatory bodies
- 5.1.4. Challenges
  - 5.1.4.1. Concern regarding adverse health outcomes of antihypertensive drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Antihypertensive Drugs Market, by Drug Class

6.1. Introduction
6.2. Alpha-Blockers
6.3. Angiotensin Converting Enzyme Inhibitors
6.4. Angiotensin Receptor Blockers
6.5. Beta-Blockers
6.6. Calcium Channel Blockers
6.7. Diuretics
6.8. Renin Inhibitors
6.9. Vasodilators

7. Antihypertensive Drugs Market, by Form

7.1. Introduction
7.2. Intravenous Injections
7.3. Oral Tablets/Capsules
7.4. Transdermal Patches

8. Antihypertensive Drugs Market, by Indication

8.1. Introduction
8.2. Primary Hypertension
8.3. Secondary Hypertension

9. Antihypertensive Drugs Market, by Distribution Channel

9.1. Introduction
9.2. Offline
9.3. Online

10. Antihypertensive Drugs Market, by End-User

10.1. Introduction
10.2. Home Care Facilities
10.3. Hospitals & Clinics

11. Americas Antihypertensive Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Antihypertensive Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Antihypertensive Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

15.1. Key Company Profiles
- 15.1.1. Abbott Laboratories
- 15.1.2. Alembic Pharmaceuticals Limited
- 15.1.3. Alkem Laboratories
- 15.1.4. Apikos Pharma
- 15.1.5. AstraZeneca PLC
- 15.1.6. Bayer AG
- 15.1.7. Boehringer Ingelheim International GmbH
- 15.1.8. Centurion Remedies Private Limited
- 15.1.9. Daiichi Sankyo Co., Ltd.
- 15.1.10. Dr. Reddy's Laboratories
- 15.1.11. F. Hoffmann-La Roche AG
- 15.1.12. Gilead Sciences, Inc.
- 15.1.13. Glenmark Pharmaceuticals Ltd.
- 15.1.14. Johnson & Johnson Services, Inc.
- 15.1.15. Lupin Ltd.
- 15.1.16. Merck & Co., Inc.
- 15.1.17. Novartis AG
- 15.1.18. Sanofi S.A.
- 15.1.19. Saphnix Lifesciences
- 15.1.20. Schwitz Biotech
- 15.1.21. Sun Pharmaceutical Industries Limited
- 15.1.22. Takeda Pharmaceutical Company Limited
- 15.1.23. Teva Pharmaceutical Industries Ltd.
- 15.1.24. United Therapeutics Corporation
- 15.1.25. Zydus Lifesciences Limited
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing